{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:14:31Z","timestamp":1761894871491,"version":"3.44.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.jns.2009.02.357","type":"journal-article","created":{"date-parts":[[2009,3,10]],"date-time":"2009-03-10T04:49:42Z","timestamp":1236660582000},"page":"120-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Rituximab for myasthenia gravis"],"prefix":"10.1016","volume":"280","author":[{"given":"Karl","family":"Stieglbauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffi","family":"Topakian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria","family":"Sch\u00e4ffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz T.","family":"Aichner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2009.02.357_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","article-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders","volume":"13","author":"Skeie","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2009.02.357_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.jns.2009.02.357_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2007.134130","article-title":"When the patient fails to respond to treatment: myasthenia gravis","volume":"7","author":"Hilton-Jones","year":"2007","journal-title":"Pract Neurol"},{"key":"10.1016\/j.jns.2009.02.357_bib4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.02.357_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.jns.2009.02.357_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2009.02.357_bib7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2009.02.357_bib8","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","article-title":"Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis","volume":"78","author":"Baek","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2009.02.357_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ncpneuro0526","article-title":"Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome","volume":"3","author":"D\u00edaz-Manera","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.jns.2009.02.357_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jns.2009.02.357_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to Rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2009.02.357_bib12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mus.21047","article-title":"Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis","volume":"38","author":"Kerkeni","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2009.02.357_bib13","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","article-title":"Invited article: inhibition of B cell functions: implications for neurology","volume":"70","author":"Dalakas","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.02.357_bib14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jns.2009.02.357_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mus.20411","article-title":"High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies","volume":"33","author":"Lin","year":"2006","journal-title":"Muscle Nerve"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X09004523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X09004523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:39:03Z","timestamp":1758382743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X09004523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":15,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0022510X09004523"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2009.02.357","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab for myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2009.02.357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}